Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35

Benzinga Newsdesk www.benzinga.com Negative 54.6%

Neg 54.6% Neu 0% Pos 0%

Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $41 to $35.